Pilgrim founder Jake Adler raises $3.25M to build military biotech — starting with rapid wound healing nanocomposites

Summary

Jake Adler's Pilgrim has raised a $3.25M seed round led by Peter Thiel's Founders Fund, Palantir-adjacent Kantos, and Refactor Capital to build advanced biotechnology for combat environments. The company's first product is a nanocomposite designed for rapid wound healing — going well beyond hemorrhage control to shorten recovery time and return troops to duty faster.

Adler's core argument is that military medicine is stuck. Tactical combat casualty care has barely evolved since Vietnam, and the battlefield is changing around it. Modern military doctrine increasingly anticipates troops deployed for weeks without medevac capability, which means the threshold for a combat casualty is shifting — it's not just a soldier who is down, it's one who can no longer fight. Quickclot, the zeolite-based hemostatic product that reached FDA clearance in nine months without human trials, is the reference point Adler builds from — his ambition is the next layer: tissue healing, not just bleeding control.

DoD as a launchpad, not an endpoint

Pilgrim's commercial logic is structured around using DoD contracts to absorb early experimental and regulatory risk, then translating validated technology into civilian markets. Adler notes that DoD-FDA memorandums allow expedited clearance pathways that move faster than FDA breakthrough designation — faster, he argues, than even Neuralink or Synchron have managed. The four-month build-and-present cycle is deliberate: Pilgrim targets rapid deployment over the traditional academic benchtop-to-battlefield crawl, which Adler describes as "totally shitty."

A second product line — a biosurveillance network for detecting biological and chemical threats — is in earlier exploration with intelligence partners.

The bioweapons gap

Adler is pointed on US vulnerability to biological attack. COVID killed 1.2 million Americans, wiped out $16 trillion in GDP, and created a 10-week operational gap in the Pacific when the USS Theodore Roosevelt was taken out of service. His read is that adversaries treat bioweapons as "poor man's nukes" — cheaper than nuclear, border-agnostic, and not requiring direct confrontation. The US policy of not building offensive bioweapons without a corresponding defensive capability leaves a dangerous asymmetry, and it's one Pilgrim is positioning to address.

Theranos legacy and the broader biotech problem

Adler is self-described bearish on biotech broadly — a striking stance for a founder in the sector. His concern is that most startups raise a few million, buy expensive equipment, and never think seriously about a path to market. His countermeasure at Pilgrim is strict benchtop validation before any government presentation, a discipline he underscores by noting he cut holes in his own legs on camera to demonstrate the wound-healing composite's efficacy.

On the Theranos parallel, he flags a live version of the same pattern: dozens of noninvasive neuromodulation companies classifying brain-computer interface devices under the FDA's general wellness category to avoid regulatory scrutiny. He expects enforcement actions to follow once any of those companies crosses meaningful scale.

Neural interfaces and China

China has been outpacing the US in neural interface patents for several years, and Adler argues its military-civil fusion doctrine means any civilian BCI company is effectively a dual-use defense asset by default. The US posture — opposition to genetic enhancement and aggressive neural modification of warfighters — slows its own timeline. On the question of whether combat-capable neural control of soldiers is plausible, Adler's answer is that it's closer than most people expect, with the primary technical barrier being spatial resolution: current noninvasive EEG-based systems can detect neural signals quickly but can't localize them precisely, a problem researchers are beginning to attack with AI-assisted signal isolation.